Development of humanized anti-EPCR mAb

2022 Fiscal Year Final Research Report

• Project/Area Number: 18K08333
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 54010:Hematology and medical oncology-related
• Research Institution: Saga University
• Principal Investigator: Fukudome Kenji 佐賀大学, 全学教育機構, 教授 (50284625)
• Project Period (FY): 2018-04-01 – 2023-03-31
• Keywords: プロテインC / 受容体」 / モノクローナル抗体 / 重症マラリア

Outline of Final Research Achievements

We generated an anti-human EPCR monoclonal antibody from rat spleen. It prevents infection of severe malaria without affecting to anti-coagulation functions of EPCR. We determined the gene sequence of variable region of this antibody. We constructed a plasmid which produces of chimeric antibody with human conserved region. By transfection and selection, we established a HEK293 cell line which stably produces the antibody. Highly purified antibody was able to be obtained from the supernatants of serum-free culture. We are characterizing this material to apply clinical use to malaria infection.

Free Research Field

血栓症

Academic Significance and Societal Importance of the Research Achievements

現在行われている低分子化合物による治療法には、薬剤抵抗変異の共通問題がある。抗体を利用した新たな治療法の選択肢ができることで、現状を海瀬できる可能性がある。